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Aim
To determine vasoactive intestinal peptide (VIP) levels
outside migraine attacks in peripheral blood as a potential
biomarker for chronic migraine (CM).
Methods
Women older than 17 and diagnosed as CM were
recruited. Matched women with no headache history and
with episodic migraine (EM) served as controls, together
with a series of patients with cluster headache in a pain-
free period. VIP levels were determined in samples
obtained from the antecubital vein by ELISA outside a
migraine attack and having taken no symptomatic medica-
tion. Due to ethical reasons, preventatives were not
stopped.
Results
We assessed plasma samples from 119 women with CM,
33 healthy women, 51 matched women with EM and 18
patients (16 males) with cluster headache matched for age.
VIP levels were significantly increased in CM (165.1 pg/
ml) as compared to control healthy women (88.5 pg/ml)
and episodic cluster headache patients (101.1 pg/ml). VIP
levels in EM (134.9 pg/ml) were significantly higher as
compared to controls and numerically lower that those of
CM. Thresholds of 71.8 and 164.5 pg/ml optimize the
sensitivity and specificity to differentiate CM from healthy
controls and EM, respectively. Variables such as age, CM
duration, the presence of aura, analgesic overuse, depres-
sion, fibromyalgia, vascular risk factors, history of triptan
consumption or kind of preventative treatment did not
influence VIP levels.
Conclusion
Increased interictal VIP level measured in peripheral blood
could be a biomarker helping in CM diagnosis, though it
does not clearly differentiate between EM and CM.
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